Treatment of CNC Tumors
Provides insights into treatment by:
Identifying targetable gene fusions, mutations
Identifying microsatellite instability as a surrogate marker for the efficacy of immunotherapy
Our Solid Biopsy NGS (Next Generation Sequencing) test, custom-built to encompass all brain tumors, utilizes advanced sequencing technology and proprietary algorithms to analyse the genetic material extracted from tumor tissue samples, allowing us to provide unparalleled accuracy in diagnosis and hitherto unavailable insights to guide treatment.
Provides insights into treatment by:
Identifying targetable gene fusions, mutations
Identifying microsatellite instability as a surrogate marker for the efficacy of immunotherapy
In a limited number of cases, where the diagnosis is not apparent, a methylation classifier will be used to make a diagnosis. This will also apply to tumors where a methylation classification system has been mandated by the WHO.
Exsegen’s own patented similarity match – Based on the histopathology and the molecular features of the tumor, the sample is matched using AI and ML algorithms with a large number of samples that have already been analysed by Exsegen. This gives further credence to the diagnosis that is being made. In case of no match, an alternative confirmatory test may be suggested.
Histopathology reporting is done on a standardized digital pathology platform by neuropathologists
India’s first custom made brain tumor NGS panel that detects all brain tumor relevant mutations, gene fusions and Copy Number Variations
Sequencing depth of > 500; following the best practice from around the world
100% compliant with ALL WHO recommendations
Single-run custom molecular testing platform that minimizes time to diagnosis and increases accuracy. We hope to issue a report within ONE week from sample collection.
Formalin-fixed paraffin embedded (FFPE) tissue specimens is used for preparing slides for histopathological evaluation using an integrated digital pathology system.
The process begins with the extraction of DNA from brain tumor samples embedded in the Formalin Fixed Paraffin Embedded (FFPE) tissue blocks.
The extracted DNA is then fragmented and ‘tagged’ at both ends to enable high throughput sequencing and fragment identification.
Rapid and high-throughput analysis of the prepared DNA library is performed using next-generation sequencing technology (NGS) on the Illumina platform.
The raw sequencing data is processed and analyzed using sophisticated bioinformatics algorithms and computational tools. This step involves mapping the sequencing reads to the reference genome, identifying genetic variants, and interpreting their potential significance in the context of CNS tumors. Gene mutations, copy number alterations, gene fusions, microsatellite status and tumor mutation burden are identified.
An integrated layered diagnosis (as mandated by the WHO) is formulated using a combination of histopathological and molecular data.
Partner with us and join our mission to revolutionize brain tumor diagnostics and management - connect with us today
Get in Touch